Clinical Edge Journal Scan

Curcumin supplementation may improve metabolic, inflammatory, and obesity markers in women with RA


 

Key clinical point: Curcumin consumption for 8 weeks as a part of an integrated approach could help modulate metabolic factors, inflammation, and adiposity in women with rheumatoid arthritis (RA) .

Major finding: After 8 weeks, insulin resistance, erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein, and triglycerides improved significantly in the curcumin supplementation vs. placebo group (all P < .05). Moreover, curcumin supplementation significantly decreased mean weight, body mass index, and waist circumference by 0.45% ( P < .001), 0.57% ( P = .003), and 0.23% ( P = .008), respectively, vs. no significant changes observed in placebo group.

Study details: The findings come from a randomized, double-blind, placebo-controlled clinical trial including 44 women with RA randomly assigned to either curcumin supplementation (500 mg/day; n = 22) or placebo (n = 22) for 8 weeks.

Disclosures: This study was supported by Research Vice-Chancellor and Nutrition Research Center of Tabriz University of Medical Sciences, Tabriz, Iran. The authors declared no conflicts of interest.

Source: Pourhabibi-Zarandi F et al. Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2022 (Feb 17). Doi: 10.1002/ptr.7422

Recommended Reading

Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
MDedge Rheumatology
RA: Early pain relief and better quality of life with baricitinib vs. methotrexate
MDedge Rheumatology
Baricitinib prevents joint deterioration independent of disease activity in RA
MDedge Rheumatology
No effect of additional COVID-19 vaccine dose on RA disease activity
MDedge Rheumatology
Satisfactory immune response to PCV-13 in RA patients receiving upadacitinib
MDedge Rheumatology
Predictors of flare following remission and treatment withdrawal in early RA
MDedge Rheumatology
Temporary methotrexate withdrawal boosts anti-SARS-CoV-2 immunogenicity in RA
MDedge Rheumatology
Real-world study finds increased remission with fewer corticosteroids and more biologics in RA
MDedge Rheumatology
Higher intake of coffee and decaffeinated coffee linked to risk of developing RA
MDedge Rheumatology
Long-term use of fostamatinib may increase the risk for malignant neoplasm in RA
MDedge Rheumatology